Melbourne, May 19, 2010 (ABN Newswire) - Australia’s regenerative medicine company, Mesoblast Limited (ASX:MSB) (ADR:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration (FDA) to begin Phase 2 clinical trials of its “off-the-shelf” or allogeneic stem cell product NeoFuse(TM) for fusion of the cervical spine in the neck. As with all of Mesoblast’s previous Investigational New Drug (IND) submissions, FDA clearance was obtained within the minimum 30-day period.
